Temple Hotels Inc(TSE:TPH)

Website
Google Finance
Filing

Feb. 26, 2018
Q4 2017 Data
Price: $2.57, Share outstanding 25.3m. Cap: $64m
1.Basic Information
(1) History 
The company was IPOed in early 2007 at a REIT trust. At that time, it only has a 180-room hotel in Moose Jaw, Saskatchewan called Temple Gardens Hotel and Spa. It was externally managed by Shelter Properties Ltd., a company controlled by Arni Thorsteinson who is also the CEO of Temple REIT.

Since 2007, the company pursued pretty aggressive growth by acquiring more hotels, especially at 2007 and 2013, by end of 2014, it had 32 hotels with around 4100 rooms. The growth was mainly done by mortgage and debts which made it became very high leveraged. It became a problem when west Canada's economy trended down because of the drop in oil price.

In 2014, Morguard Corporation, a multi-billion public RE company run by Rai Sahi, started to purchase the company's shares and collected 4.7m shares which are 11.5% of total 41m shares by year-end.

In May 2015, Centennial Group Limited, a 5% shareholder, started a proxy fight with the company and it led to new board election including Rai Sahi from Morguard and two others from Centennial.

In later 2015, the company did a private offering of $40m for $1.1/share. At end of 2015, Morguard, through the private offering, owned 30m shares which are 39% of total 78m outstanding shares.

On April 01, 2016, the company transferred its management from Shelter to Morguard. At the same time, Rai Sahi replaced Arni Thorsteinson as new CEO of the company.

In Dec. 2016, the company did another $50m private offering for $0.67/share. Increased total shares to 151m. Morguard increased its shares to 85m which is 56% of total shares.

In June 2017, the company did 6 for 1 share consolidation. As a result, it now has 25.3m shares. Among which Morguard has 14.1m which is around 56% of total shares.

(2) Business-related:


(3) Management.
Rai Sahi is the key person in this company right now. He is an immigrate from India in 1971. After working for several years, he created his own trucking business and later entered real estate at around 1996. His company is now called Morguard Corporation which owns and manages over $17b real estate.

(4) Debt and Credit Facility.
By Q4 2017, it has following debts:
(1) $370m in mortgage debt. The average interest rate is around 5%. It was not in compliance with coverage ratios with 6 mortgages total around $100m.
(2) $13.5m Revolving loan provided by Morguard. Prime rate +2%.

(3) $41m convertible loan due on Sept. 30, 2020. Interest rate 7.25%. There is $2.2m redemption each year. Converting price $9.75

(4) $34m convertible loan due Mar. 2018. It will be repaid since Morguard issue a new $35m facility for $6.5% on Feb. 2018.

Totally the company has around $450m in debt. It has to pay around $25m in interest. Also, the company's total asset is around $460m which is almost the same as the total debt. Mainly because there was quite a lot impairment in the past few years.

(5) Insider holding, options, Insider trading info, share buyback.
Rai Sahi: Holds 14.1m(56%) shares through Morguard Corporation.

(6) Employee numbers
Not important

(7) Industry comparison.


(8) Major events



2. Financial data.
3. Valuation
(1) With distressed oil price, the company still be able to generate around $14m in Fund From Operation(FFO). While current Cap is 64m. The yield of FFO to market cap is around 21.5%. By average, REIT should be traded less than 10% of FFO. That gives room to double the current price if it is priced fairly.

(2) Currently, all the hotels in Alberta simply are not making money. If the company sell those hotels, the company will be able to deduct 2/5 of its debt and the profit will still be the same. However, that doesn't reduce leverage ratio that much since currently the company's equity is really low.

(3) Before 2015, the appraised value is always higher than the cost of acquiring those hotels. Now the book value of all those hotels is around $430m while the original cost is over $730 by my estimation. I think the fair value of those hotels should be no less than $550m. That gives a $120m in addition to book value which is around $4.8/share.

4. Risk
(1)Unlike OTEL, who's earning is stable but the debt interest rate is too high. This company needs to improve its profitability before it can make it to lower leverage. Although current RevPar is low and is improving, there is the risk that it might go down again.

(2) Competition from lodge sharing service like Airbnb might be a threat to the whole lodging industry.

(3) Now with both convertible debt been extended to the year 2020, although its debt level is high and it is not in compliance in some mortgage debt terms, its debt actually is not a big issue for now. It can pay down some individual mortgages if the talk fails. Also, it has the choice to sell some of the nono performing hotels. Most of the hotels are booked below the purchase price now.

5. Conclusion
The current price is significantly undervalued the company's real asset value. It expects the company to raise more capital and dilute existing shares. While I feel it is more likely won't need to issue any new shares and the business might also be getting better.

6.Links

Interview with Rai Sahi

Apr. 08, 2019
Price: $1.74. Shares: 50m. Cap: $87m.
(1) For 2018, it only generates $11.2 in FFO which is lower than last year's $14m.

(2) I was wrong that the company did have to raise money to cover debt repayment. It did a 1:1 share offering at $1.75/share which doubled the share count to 50m. Most of the shares were taken by Morguard. As a result, all convertible shares were redeemed. It owns Morguard by $65m. I estimated it will save $3m in annual interest which will be added to FFO.

(3) Assume by 2021, it can generate $18m in FFO. at 8% rate, it supports a $225m cap which is $4.5 share price. 

HLS Therapeutics(CVE:HLS)

Website
Yahoo Finance
Filing

Feb. 09, 2017
Q3 2017 Data
Price: US$9.25, Shares: 27m. Cap: $313m?
1.Basic Information
(1) History 
It was created by the former management of Biovail in 2015.  HLS raised US$385m(USD$200m from stock offering of US$10/share and US$185m debt) and acquired the North American rights to Clozaril, a medicine for resistant schizophrenia for US$305m from Novartis.  At Dec. 2017, it entered an agreement with Automodular (CVE:AM.H), a shell company to do a reverse merger at US$9.25/share valuation. The vote is scheduled at Mar. 6 and expect to close shortly after it.

(2) Business-related:
Colozaril: Acquired in August 2015 for $305m. It generated $46m and $36m revenue for 2016 and 3Q of 2017.

It also acquired rights to market Absorica in the US from Galephar Pharmaceutical for $17m payment plus future royalty,  Absorica is an oral pill to treat nodular acne. In the first 3Q, the company received US19m in revenue which seems well-exceeded expectation. Partially it was because one of its competitors called back a product since early 2017.

The company also acquired distribution right of Vascepa in Canada at Sept. 2017 with $5m up-front payment and following payments. Vascepa is an omega 3 prescription drug by Amarin Corporation plc (NASDAQ:AMRN). It generated revenue in US about $46 in Sept. 2017 quarter.

(3) Management.
Biovail Filing
Most of the management previously were worked for Biovail.  Biovail is a public Canadian drug company which had committed accounting fraud at around 2001 to 2003 time. At 2010, it merged with Valeant. In 2015, Valeant was also criticized for price hiking of its drugs and the stock dropped by 90% since then. However, based on the below information. The management team of HLS was not part of the troubled period for both companies.

Chairman Bill Wells:  He joined Biovail in 2005 as an independent director. At that time he was the CFO of Loblaws. After former CEO Eugene Melnyk left Biovail in 2017, he became the CEO of Biovail from 2008 and 2010. He led the turnaround and the merger with Valeant. I think he did a good job on that. He left the company right after the merge.

CEO Gregory Gubitz: SVP of Biovail from 2006 to 2010.

COO Gilbert Godin: SVP, COO of Biovail from 2006 to 2011.

Chief Scientific Advisor Chris Fibiger: CSA of Biovail from 2008 to 2010.

VP  Integration Management Carmel Daughtery: VP Integration Management of Biovail from 2005 to 2010

VP Intellectual Property Rochelle K. Seide: VP Intellectual Property of Biovail from 2009 to 2011


(4) Debt and Credit Facility.
Currently, there is US$150m?? debt outstanding. Currently, it has US35.7m in cash. After the merger, it should have around US$55m in cash.

(5) Insider holding, options, Insider trading info, share buyback.
Bill Wills: 1.2m shares + 250k options +260k PSU.  5.4%
Joe Maclean(Director): 1.9m shares +250k options +260k PSU.  7.5%.
Gregory Gubitz:  667k shares + 250k options + 260k PSU. 3.7%
Gilbert Godin: 900k shares + 250k options + 260 PSU. 4.4%.

(6) Employee numbers


(7) Industry comparison.


(8) Major events



2. Financial data.


3. Valuation
(1)Currently,  it has US$180m in equity and US$30m in losses. It has 25,277,997 in total shares. For 2016 and 3Q 2017, it generated US38m and US$40m in EBITDA. By estimate, it might generate US$55m in EBIDTA at 2017. It has cash of US$35.7m and has a debt balance of around US$156m.

(1) . If using US$55m as annual EBITDA,  US$9.25 as current price, its EV=9.25*25.3+156-35.7=$354m. EV/EBITDA = 354/55=6.5. Not that high actually. If adding AM's new equity and cash, the EV will still be the same since the Cash and added equity will be even out.


4. Risk
(1) The public reception of any person related to Biovail and Valeant is pretty bad. The company might be precepted as a replica of Biovail or Valeant which is not good for a public company. However, since the management is not involved in the bad deed of both companies. Eventually, the financial number will speak for itself.

(2) The good Absorica performance is partly due to competitor's callback. Once it is back, Absorica revenue might down significantly.

(3) All the drugs might subject to competition from new drug from generics.

5. Conclusion
Although this is a new stock, it generates steady cash and EV/EBITDA. If it can keep business stable, the price is acceptable. If it can acquire more drugs, then this could a very good one.

6.Links

Mar. 16, 2018
Current Price $11.5, shares 27.3m. Cap: $314m
1. The new HLS share started trading at Mar. 14. Current price equals roughly US$8.84 which is lower than the $9.25/share price and all previous private placement.

2. Assuming US$60m EBITDA at 2020, 10 EV/EBITDA, US$100m net debt, 1.3 USD/CAD rate. 28m shares. Its price can be (60*10-100)*1.3/28=CAD$23.2.